Genetic testing to predict response to lung cancer immunotherapy
Part of Cancer, Lungs & breathing clinical trials.
This study looks at genetic (DNA) information to find a marker that can help predict whether immunotherapy will work for lung cancer. If you’ve already received an immune checkpoint inhibitor, your tumor/genetic data may be analyzed to look for clues that guide treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have lung cancer that has been confirmed by pathology (biopsy/surgery results)
- You have received an immune checkpoint inhibitor (a type of immunotherapy)
- You are able to provide the genetic/tumor information the study needs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well immune checkpoint medicines (with or without chemotherapy) work for lung cancer, and looks for biomarkers—tests that may help predict who benefits. It may help you access a structured treatment plan and additional response testing.
This study looks for blood or tissue markers that can predict who benefits from immunotherapy given before surgery for non-small cell lung cancer. It may help doctors better choose treatment in the future.
This study looks at how tumors respond to chemotherapy plus immunotherapy before surgery for non-small cell lung cancer. It uses genetic tests on the tumor and blood to personalize treatment and possibly improve outcomes.
This study looks at the genetic makeup of lung cancer tumors after patients receive immunotherapy before surgery. It aims to understand why some tumors do not completely disappear and may help guide future treatments.
This study looks at genetic material from tumor samples to find patterns that can predict whether immunotherapy will work for people with advanced non-small cell lung cancer (NSCLC). The goal is to improve how doctors choose treatments for each patient.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.